HER2 assessment to define outcomes for breast cancer patients treated with neoadjuvant therapy

被引：0
|
作者：
Cheng, Huan [1 ]
Bai, Yalai [1 ]
Sikov, Willliam [2 ]
Sinclair, Natalie [2 ]
Abu-Khalaf, Maysa [1 ]
Harris, Lyndsay N. [1 ]
Rimm, David L. [1 ]
机构：
[1] Yale Univ, New Haven, CT USA
[2] Brown Univ, Providence, RI 02912 USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-705
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
705
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Pathologic response to neoadjuvant therapy in HER2 positive/oestrogen receptor positive breast cancer patients
    Gasol Cudos, A.
    Morales, S.
    Rodriguez Galindo, A.
    Velasco Sanchez, A.
    Serrate Lopez, A.
    Mele Olive, J.
    Canosa Morales, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S333 - S333
  • [32] THE UPFRONT THERAPY FOR HER2 POSITIVE BREAST CANCER PATIENTS
    Iwata, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 76 - 76
  • [33] HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment
    Altundag, Kadri
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (01) : 261 - 261
  • [34] HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment
    Kadri Altundag
    Breast Cancer Research and Treatment, 2019, 175 : 261 - 261
  • [35] Stability of HER2 Expression in Residual Breast Cancer Following Neoadjuvant Anti-HER2 Therapy
    Mir, Mariam O.
    Sahoo, Sunati
    Fang, Yisheng
    Peng, Yan
    Hwang, Helena
    Czapla, Agata
    Koduru, Prasad
    Sarode, Venetia
    LABORATORY INVESTIGATION, 2018, 98 : 91 - 91
  • [36] Optimal Regimen of Neoadjuvant Systemic Therapy for HER2 Positive Early Breast Cancer
    Lo, C.
    Wang, M. -Y.
    Kuo, W. -H.
    Lee, Y. -H.
    Tsai, L. -W.
    Lu, Y. -S.
    Lin, C. -H.
    Chang, D. -Y.
    Chen, W. -W.
    Huang, C. -S.
    BREAST, 2023, 68 : S61 - S62
  • [37] Factors influencing HER2 discordance in nonmetastatic breast cancer and the role of neoadjuvant therapy
    Ebinc, Senar
    Oruc, Zeynep
    Sezgin, Yasin
    Karhan, Ogur
    Bilen, Erkan
    Yerlikaya, Halis
    Kalkan, Ziya
    Urakci, Zuhat
    Kucukoner, Mehmet
    Kaplan, Muhammet Ali
    Isikdogan, Abdurrahman
    FUTURE ONCOLOGY, 2022, 18 (30) : 3399 - 3408
  • [38] Cardiotoxicity in HER2 positive breast cancer patients treated with trastuzumab
    Lopez, M.
    Minguito Carazo, C.
    Delgado Sillero, I.
    Rojas Piedra, M.
    Tavara Silva, B.
    Lopez-Gonzalez, A.
    Castanon Lopez, C.
    Nieto Mangudo, B.
    Pedraza Lorenzo, M.
    Rodriguez Sanchez, A.
    Diz Tain, P.
    De Sande Gonzalez, L. M.
    Medina Valdivieso, S.
    Lopez Gonzalez, L.
    Honrado Franco, E.
    Garcia-Palomo, A.
    Sanchez-Cousido, L. F.
    ANNALS OF ONCOLOGY, 2020, 31 : S332 - S332
  • [39] Evolution and Clinical Significance of HER2 Status after Neoadjuvant Therapy for Breast Cancer
    Shang, Jiuyan
    Liu, Yueping
    LABORATORY INVESTIGATION, 2023, 103 (03) : S209 - S209
  • [40] The influence of hormone receptor status and HER1 and HER2 expression on the response to neoadjuvant therapy in breast cancer patients
    Bonigliere, L.
    Torrisi, R.
    Pruneri, G.
    Colleoni, M.
    Viale, G.
    LABORATORY INVESTIGATION, 2008, 88 : 24A - 24A
12345